{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T13:51:05Z","timestamp":1783086665082,"version":"3.54.6"},"reference-count":66,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T00:00:00Z","timestamp":1600819200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002975","name":"Dainippon Sumitomo Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002975","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological Sciences"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.jphs.2020.09.006","type":"journal-article","created":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T09:10:03Z","timestamp":1602148203000},"page":"42-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Safety and effectiveness of oral blonanserin for schizophrenia: A review of Japanese post-marketing surveillances"],"prefix":"10.1016","volume":"145","author":[{"given":"Yoshifumi","family":"Inoue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimiko","family":"Tsuchimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jphs.2020.09.006_bib1","first-page":"461","article-title":"Preclinical characteristic and clinical positioning of Blonanserin for schizophrenia","volume":"11","author":"Murasaki","year":"2008","journal-title":"Jpn J Clin Psychopharmacol"},{"key":"10.1016\/j.jphs.2020.09.006_bib2","first-page":"2059","article-title":"Clinical evaluation of Blonanserin for schizophrenia \u2013A double-blind trial comparing Blonanserin with haloperidol","volume":"10","author":"Murasaki","year":"2007","journal-title":"Jpn J Clin Psychopharmacol"},{"key":"10.1016\/j.jphs.2020.09.006_bib3","first-page":"297","article-title":"Clinical evaluation of Blonanserin for schizophrenia \u2013A randomized study comparing Blonanserin with risperidone","volume":"11","author":"Miura","year":"2008","journal-title":"Jpn J Clin Psychopharmacol"},{"issue":"2","key":"10.1016\/j.jphs.2020.09.006_bib4","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/a-0574-0088","article-title":"Efficacy, tolerability, and safety of blonanserin in schizophrenia: an updated and extended systematic review and meta-analysis of randomized controlled trials","volume":"52","author":"Kishi","year":"2019","journal-title":"Pharmacopsychiatry"},{"issue":"2","key":"10.1016\/j.jphs.2020.09.006_bib5","first-page":"295","article-title":"Clinical evaluation of aripiprazole in schizophrenic patients: a comparative double\u2013blind study with haloperidol","volume":"9","author":"Ishigooka","year":"2006","journal-title":"Jpn J Clin Psychopharmacol"},{"issue":"4","key":"10.1016\/j.jphs.2020.09.006_bib6","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1046\/j.1440-1819.2001.00882.x","article-title":"Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double\u2013blind olanzapine trial","volume":"55","author":"Ishigooka","year":"2001","journal-title":"Psychiatr Clin Neurosci"},{"key":"10.1016\/j.jphs.2020.09.006_bib7","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2147\/NDT.S59861","article-title":"Effect of blonanserin on cognitive and social function in acute phase Japanese schizophrenia compared with risperidone","volume":"10","author":"Hori","year":"2014","journal-title":"Neuropsychiatric Dis Treat"},{"issue":"3","key":"10.1016\/j.jphs.2020.09.006_bib8","doi-asserted-by":"crossref","first-page":"423","DOI":"10.9758\/cpn.2019.17.3.423","article-title":"Switching antipsychotics to blonanserin in patients with schizophrenia: an open-label, prospective, multicenter study","volume":"17","author":"Woo","year":"2019","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"10.1016\/j.jphs.2020.09.006_bib9","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ajp.2016.08.014","article-title":"Effectiveness of blonanserin for patients with drug treatment-resistant schizophrenia and dopamine supersensitivity: a retrospective analysis","volume":"24","author":"Tachibana","year":"2016","journal-title":"Asian J Psychiatr"},{"key":"10.1016\/j.jphs.2020.09.006_bib10","series-title":"LONASEN (blonanserin) [package insert]","year":"2020"},{"issue":"3","key":"10.1016\/j.jphs.2020.09.006_bib11","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jphs.2015.01.007","article-title":"Blonanserin extensively occupies rat dopamine D3 receptors at antipsychotic dose range","volume":"127","author":"Baba","year":"2015","journal-title":"J\u00a0Pharmacol Sci"},{"key":"10.1016\/j.jphs.2020.09.006_bib12","first-page":"845","article-title":"Dopamine-serotonin antagonist: receptor-binding profile of a novel antipsychotic Blonanserin","volume":"9","author":"Murasaki","year":"2008","journal-title":"Jpn J Clin Psychopharmacol"},{"issue":"1","key":"10.1016\/j.jphs.2020.09.006_bib13","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.schres.2014.06.035","article-title":"Lifetime use of antipsychotic medication and its relation to change of verbal learning and memory in midlife schizophrenia \u2014 an observational 9-year follow-up study","volume":"158","author":"Husa","year":"2014","journal-title":"Schizophr Res"},{"issue":"3","key":"10.1016\/j.jphs.2020.09.006_bib14","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/acps.12374","article-title":"Second-generation antipsychotic effect on cognition in patients with schizophrenia--a meta-analysis of randomized clinical trials","volume":"131","author":"Nielsen","year":"2015","journal-title":"Acta Psychiatr Scand"},{"issue":"6","key":"10.1016\/j.jphs.2020.09.006_bib15","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S0278-5846(02)00221-X","article-title":"The effect of chronic treatment with typical and atypical antipsychotics on working memory and jaw movements in three- and eighteen-month-old rats","volume":"26","author":"Rosengarten","year":"2002","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"9","key":"10.1016\/j.jphs.2020.09.006_bib16","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1038\/nn.4616","article-title":"Antipsychotic-induced Hdac2 transcription via NF-\u03baB leads to synaptic and cognitive side effects","volume":"20","author":"Ibi","year":"2017","journal-title":"Nat Neurosci"},{"issue":"2","key":"10.1016\/j.jphs.2020.09.006_bib17","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s12325-013-0004-9","article-title":"Cariprazine in bipolar disorder: clinical efficacy, tolerability, and place in therapy","volume":"30","author":"Citrome","year":"2013","journal-title":"Adv Ther"},{"issue":"6","key":"10.1016\/j.jphs.2020.09.006_bib18","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1093\/ijnp\/pyy004","article-title":"Comparison of dopamine D3 and D2 receptor occupancies by a single dose of blonanserin in healthy subjects: a Positron emission tomography study with [11C]-(+)-PHNO","volume":"21","author":"Tateno","year":"2018","journal-title":"Int J Neuropsychopharmacol"},{"issue":"213","key":"10.1016\/j.jphs.2020.09.006_bib19","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/978-3-642-25758-2_7","article-title":"The role of dopamine D(3) receptors in antipsychotic activity and cognitive functions","author":"Gross","year":"2012","journal-title":"Handb Exp Pharmacol"},{"issue":"10","key":"10.1016\/j.jphs.2020.09.006_bib20","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.biopsych.2013.11.023","article-title":"Selective overexpression of dopamine D3 receptors in the striatum disrupts motivation but not cognition","volume":"76","author":"Simpson","year":"2014","journal-title":"Biol Psychiatr"},{"issue":"2","key":"10.1016\/j.jphs.2020.09.006_bib21","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/schbul\/sbz095","article-title":"Are negative symptoms Merely the \u201creal world\u201d consequences of deficits in social cognition?","volume":"46","author":"Pelletier-Baldelli","year":"2020","journal-title":"Schizophr Bull"},{"issue":"1\u20132","key":"10.1016\/j.jphs.2020.09.006_bib22","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0006-8993(00)02247-2","article-title":"The dopamine D3 receptor antagonist nafadotride inhibits development of locomotor sensitization to amphetamine","volume":"867","author":"Richtand","year":"2000","journal-title":"Brain Res"},{"issue":"2","key":"10.1016\/j.jphs.2020.09.006_bib23","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1755-5949.2010.00162.x","article-title":"All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2(high) receptors","volume":"17","author":"Seeman","year":"2011","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.jphs.2020.09.006_bib24","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejphar.2018.04.014","article-title":"Lack of dopamine supersensitivity in rats after chronic administration of blonanserin: comparison with haloperidol","volume":"830","author":"Hashimoto","year":"2018","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jphs.2020.09.006_bib25","first-page":"769","article-title":"Safety and efficacy of Blonanserin administered for 12 weeks in daily clinical practice in patients with schizophrenia \u2013Results of a post-marketing surveillance of blonanserin-","volume":"18","author":"Masuda","year":"2015","journal-title":"Jpn J Clin Psychopharmacol"},{"key":"10.1016\/j.jphs.2020.09.006_bib26","first-page":"617","article-title":"One-year follow-up of a Blonanserin post-marketing surveillance in schizophrenia patients \u2013Long-term safety and efficacy of Blonanserin in daily clinical practice-","volume":"19","author":"Nagao","year":"2016","journal-title":"Jpn J Clin Psychopharmacol"},{"key":"10.1016\/j.jphs.2020.09.006_bib27","first-page":"471","article-title":"Results of post-marketing study of Blonanserin in antipsychotic-na\u00efve patients with first-episode schizophrenia \u2013Safety and efficacy of Blonanserin administered for 12 weeks in daily clinical practice-","volume":"19","author":"Kawaguchi","year":"2016","journal-title":"Jpn J Clin Psychopharmacol"},{"key":"10.1016\/j.jphs.2020.09.006_bib28","first-page":"1745","article-title":"Results of post-marketing surveillance study of Blonanserin in schizophrenic patients with diabetes \u2013Safety and efficacy of Blonanserin administered for 12 months in daily clinical practice-","volume":"19","author":"Tsuchimori","year":"2016","journal-title":"Jpn J Clin Psychopharmacol"},{"key":"10.1016\/j.jphs.2020.09.006_bib29","first-page":"1311","article-title":"Results of post-marketing surveillance study of Blonanserin in acute exacerbation phase schizophrenic patients \u2013Treatment status, safety and efficacy of Blonanserin administered for 12 weeks in daily clinical practice-","volume":"20","author":"Tsuchimori","year":"2017","journal-title":"Jpn J Clin Psychopharmacol"},{"key":"10.1016\/j.jphs.2020.09.006_bib30","volume":"vol. 39","year":"2020"},{"key":"10.1016\/j.jphs.2020.09.006_bib31","first-page":"1347","article-title":"Safety and efficacy of aripiprazole in actual clinical settings: findings form drug-use survey in patients with schizophrenia","volume":"15","author":"Takayama","year":"2012","journal-title":"Jpn J Clin Psychopharmacol"},{"key":"10.1016\/j.jphs.2020.09.006_bib32","first-page":"1107","article-title":"Final report of the postmarketing prospective study in patients with schizophrenia using olanzapine","volume":"11","author":"Nishiuma","year":"2008","journal-title":"Jpn J Clin Psychopharmacol"},{"key":"10.1016\/j.jphs.2020.09.006_bib33","first-page":"1511","article-title":"The social functional outcome of being naturalistically treated with paliperidone extended-release in patients with schizophrenia","volume":"11","author":"Nakagawa","year":"2015","journal-title":"Neuropsychiatric Dis Treat"},{"issue":"4","key":"10.1016\/j.jphs.2020.09.006_bib34","doi-asserted-by":"crossref","first-page":"354","DOI":"10.4306\/pi.2012.9.4.354","article-title":"Prominent clinical dimension, duration of illness and treatment response in schizophrenia: a naturalistic study","volume":"9","author":"Buoli","year":"2012","journal-title":"Psychiatr Investig"},{"issue":"1","key":"10.1016\/j.jphs.2020.09.006_bib35","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2217\/npy.10.2","article-title":"Duration of illness and duration of untreated illness in relation to drug response in psychiatric disorders","volume":"1","author":"Altamura","year":"2011","journal-title":"Neuropsychiatry"},{"issue":"1","key":"10.1016\/j.jphs.2020.09.006_bib36","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41537-017-0034-4","article-title":"The effect of duration of untreated psychosis and treatment delay on the outcomes of prolonged early intervention in psychotic disorders","volume":"3","author":"Albert","year":"2017","journal-title":"NPJ Schizophr"},{"issue":"2 Suppl","key":"10.1016\/j.jphs.2020.09.006_bib37","first-page":"1","article-title":"Practice guideline for the treatment of patients with schizophrenia, second edition","volume":"161","author":"Lehman","year":"2004","journal-title":"Am J Psychiatr"},{"issue":"10","key":"10.1016\/j.jphs.2020.09.006_bib38","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2165\/11314280-000000000-00000","article-title":"Antipsychotic drugs for first-episode schizophrenia: a comparative review","volume":"23","author":"Salimi","year":"2009","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.jphs.2020.09.006_bib39","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/schbul\/sbp116","article-title":"The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements","volume":"36","author":"Buchanan","year":"2010","journal-title":"Schizophr Bull"},{"issue":"5","key":"10.1016\/j.jphs.2020.09.006_bib40","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3109\/15622975.2012.696143","article-title":"World federation of societies of biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance","volume":"13","author":"Hasan","year":"2012","journal-title":"World J Biol Psychiatr"},{"issue":"9690","key":"10.1016\/j.jphs.2020.09.006_bib41","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(09)60995-8","article-title":"Schizophrenia","volume":"374","author":"van Os","year":"2009","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jphs.2020.09.006_bib42","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0920-9964(99)00191-7","article-title":"Mortality and causes of death in schizophrenia in Stockholm county, Sweden","volume":"45","author":"Osby","year":"2000","journal-title":"Schizophr Res"},{"issue":"1","key":"10.1016\/j.jphs.2020.09.006_bib43","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.schres.2005.07.014","article-title":"Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III","volume":"80","author":"McEvoy","year":"2005","journal-title":"Schizophr Res"},{"issue":"2","key":"10.1016\/j.jphs.2020.09.006_bib44","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/schbul\/sbr148","article-title":"Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis","volume":"39","author":"Mitchell","year":"2013","journal-title":"Schizophr Bull"},{"issue":"2","key":"10.1016\/j.jphs.2020.09.006_bib45","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/hup.2295","article-title":"Low prevalence of metabolic syndrome and its prediction in Japanese inpatients with schizophrenia","volume":"28","author":"Suzuki","year":"2013","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.jphs.2020.09.006_bib46","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1744-859X-10-21","article-title":"Comparison of prevalence of metabolic syndrome in hospital and community-based Japanese patients with schizophrenia","volume":"10","author":"Sugawara","year":"2011","journal-title":"Ann Gen Psychiatr"},{"issue":"1","key":"10.1016\/j.jphs.2020.09.006_bib47","first-page":"12","article-title":"Pharmacological mechanisms underlying the association of antipsychotics with metabolic disorders","volume":"40","author":"Miron","year":"2014","journal-title":"Curr Health Sci J"},{"issue":"2","key":"10.1016\/j.jphs.2020.09.006_bib48","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2337\/diacare.27.2.596","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"27","year":"2004","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.jphs.2020.09.006_bib49","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nrendo.2011.156","article-title":"Metabolic and cardiovascular adverse effects associated with antipsychotic drugs","volume":"8","author":"De Hert","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.jphs.2020.09.006_bib50","first-page":"755","article-title":"Effect of quetiapine fumarate on blood glucose levels in schizophrenic patients \u2013 a follow-up study of subjects participating in the Observational Study in general practice","volume":"21","author":"Nakamura","year":"2006","journal-title":"Jpn J Psychiatr Treat"},{"issue":"8","key":"10.1016\/j.jphs.2020.09.006_bib51","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1177\/0269881116645254","article-title":"BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment","volume":"30","author":"Cooper","year":"2016","journal-title":"J\u00a0Psychopharmacol"},{"issue":"1\u20133","key":"10.1016\/j.jphs.2020.09.006_bib52","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.schres.2006.10.009","article-title":"Body mass index, waist circumference and quality of life in individuals with schizophrenia","volume":"90","author":"Faulkner","year":"2007","journal-title":"Schizophr Res"},{"key":"10.1016\/j.jphs.2020.09.006_bib53","first-page":"2085","article-title":"Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia: retrospective analysis of postmarketing surveillance data of olanzapine in Japan","volume":"11","author":"Nishiuma","year":"2008","journal-title":"Jpn J Clin Psychopharmacol"},{"key":"10.1016\/j.jphs.2020.09.006_bib54","first-page":"1479","article-title":"The long-term safety, efficacy and effectiveness of risperidone long-acting injection in schizophrenias; Results of the post-marketing surveillance","volume":"16","author":"Wakamatsu","year":"2013","journal-title":"Jpn J Clin Psychopharmacol"},{"key":"10.1016\/j.jphs.2020.09.006_bib55","first-page":"1335","article-title":"Results of the 12-month post marketing surveillance of paliperidone palmitate in schizophrenias","volume":"20","author":"Wakamatsu","year":"2017","journal-title":"Jpn J Clin Psychopharmacol"},{"key":"10.1016\/j.jphs.2020.09.006_bib56","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.2147\/NDT.S113099","article-title":"Antipsychotic-associated weight gain: management strategies and impact on treatment adherence","volume":"13","author":"Dayabandara","year":"2017","journal-title":"Neuropsychiatric Dis Treat"},{"key":"10.1016\/j.jphs.2020.09.006_bib57","first-page":"537","article-title":"Efficacy and safety of aripiprazole in acute phase schizophrenia: findings from post-marketing surveillance","volume":"17","author":"Takayama","year":"2014","journal-title":"Jpn J Clin Psychopharmacol"},{"key":"10.1016\/j.jphs.2020.09.006_bib58","first-page":"787","article-title":"Efficacy and tolerability of quetiapine in acute schizophrenia: a post-marketing observational study of quetiapine","volume":"13","author":"Kato","year":"2010","journal-title":"Jpn J Clin Psychopharmacol"},{"key":"10.1016\/j.jphs.2020.09.006_bib59","first-page":"135","article-title":"Long-term clinical study of blonanserin for schizophrenia: a multicenter open study to determine safety and effectiveness in schizophrenic patients","volume":"11","author":"Kinoshita","year":"2008","journal-title":"Jpn J Clin Psychopharmacol"},{"key":"10.1016\/j.jphs.2020.09.006_bib60","first-page":"2241","article-title":"Long-term clinical study of blonanserin for schizophrenia: a multicenter open study to determine safety and effectiveness in schizophrenic patients (Kanagawa Region Clinical Psychopharmacology Study Group)","volume":"10","author":"Murasaki","year":"2007","journal-title":"Jpn J Clin Psychopharmacol"},{"issue":"11","key":"10.1016\/j.jphs.2020.09.006_bib61","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1097\/00005053-199211000-00007","article-title":"The positive and negative syndrome Scale and the Brief psychiatric rating Scale. Reliability, comparability, and predictive validity","volume":"180","author":"Bell","year":"1992","journal-title":"J\u00a0Nerv Ment Dis"},{"key":"10.1016\/j.jphs.2020.09.006_bib62","first-page":"1223","article-title":"Early prediction of blonanserin response in acute exacerbation phase in schizophrenic patients \u2013Results of post-marketing surveillance study of blonanserin\u2013(text in [Japanese] with English abstract)","volume":"22","author":"Tsuchimori","year":"2019","journal-title":"Jpn J Clin Psychopharmacol"},{"key":"10.1016\/j.jphs.2020.09.006_bib63","series-title":"Japanese Society of Neuropsychopharmacology Guideline for pharmacological therapy of schizophrenia (in Japanese)","year":"2017"},{"issue":"2","key":"10.1016\/j.jphs.2020.09.006_bib64","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/JCP.0b013e3182825bce","article-title":"Striatal and extrastriatal dopamine D2 receptor occupancy by a novel antipsychotic, blonanserin: a PET study with [11C]raclopride and [11C]FLB 457 in schizophrenia","volume":"33","author":"Tateno","year":"2013","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"5","key":"10.1016\/j.jphs.2020.09.006_bib65","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1001\/archpsyc.1993.01820170047006","article-title":"Time course and biologic correlates of treatment response in first-episode schizophrenia","volume":"50","author":"Lieberman","year":"1993","journal-title":"Arch Gen Psychiatr"},{"issue":"33","key":"10.1016\/j.jphs.2020.09.006_bib66","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1192\/S0007125000297687","article-title":"Pharmacotherapy of first-episode schizophrenia","volume":"172","author":"Remington","year":"1998","journal-title":"Br J Psychiatr Suppl"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861320300967?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861320300967?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T20:00:19Z","timestamp":1761163219000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347861320300967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S1347861320300967"],"URL":"https:\/\/doi.org\/10.1016\/j.jphs.2020.09.006","relation":{},"ISSN":["1347-8613"],"issn-type":[{"value":"1347-8613","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and effectiveness of oral blonanserin for schizophrenia: A review of Japanese post-marketing surveillances","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jphs.2020.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.","name":"copyright","label":"Copyright"}]}}